DirectTransfer

DirectTransfer is a pre-clinical stage biotechnology company focused on developing next-generation cell and gene therapies through its proprietary non-viral delivery platform. The company's technology is designed to enable the direct transfer of genetic material into cells without the need for viral vectors, potentially reducing manufacturing complexity and improving safety profiles. DirectTransfer aims to apply its platform across a range of therapeutic areas, with an initial focus on oncology and autoimmune diseases. By streamlining the engineering of therapeutic cells, the company seeks to make advanced cell therapies more accessible and scalable for patients in need.